Drug Trial Radar · NCT06197295
Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity
Last checked: Nov 20, 2026Latest source record: May 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jun 16, 2022
Primary completion
Jun 30, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Mackay Memorial HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 40 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To investigates the effects of combined pharmacotherapy with solifenacin and mirabegron versus solifenacin with vaginal estrogen cream in women with detrusor overactivity.
Conditions
- Urinary Bladder, Overactive
- Effect of Drug
Interventions
Solifenacin with vaginal estrogen creamDrug
Solifenacin 5mg with vaginal conjugated equine estrogen (CEE) 0.625 mg
Combination pharmacotherapyDrug
Solifenacin 5mg and Mirabegron 25mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Short form of Urinary Distress Inventory (UDI-6)Time frame: Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
- Short form of Incontinence Impact Questionnaire (IIQ-7)Time frame: Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
- Overactive Bladder Symptom Score (OABSS)Time frame: Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mackay Memorial Hospital
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.